Palliative care physicians’ recognition of patients after immune checkpoint inhibitors and immune-related adverse events
- 12 August 2021
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (1) , 775-784
Abstract
Purpose This study investigated the experience of palliative care physicians (PCPs) and their knowledge and recognition of immune checkpoint inhibitors (ICIs) and immune-related adverse events (irAEs) in clinical practice as well as the need to provide palliative care services for patients after ICI treatments. Methods A cross-sectional survey with self-administered questionnaires was conducted between February and April 2020. A total of 759 questionnaires were sent to PCPs in Japan. The changes in the PCPs’ knowledge and recognition of ICIs and irAEs due to the increased experiences of treating patients after ICI treatments were analyzed. Results Four hundred ninety-two responses (64.8%) were analyzed. Only 15.0% of respondents had no experience of patients after ICI treatments, while 53.9% had experience of more than six patients. On the other hand, 40% of respondents had no experience of patients with suspected irAEs, while only 13.4% had experience of more than six patients. Respondents with more experience of patients after ICI treatments or those with suspected irAEs had extensive knowledge of ICIs and irAEs, were more confident in treating these patients, and tended to consider irAEs as therapeutic indications. The majority of respondents required guidelines and efficient consultation systems with oncologists. Conclusion This study demonstrated that PCPs with experience had extensive knowledge and confidence of ICIs and irAEs and tended to recognize irAEs as therapeutic indications. The establishment of a more intimate relationship between PCPs and oncologists is important for providing better treatment for these patients.Keywords
Funding Information
- Ministry of Health, Labour and Welfare (19EA1011)
This publication has 30 references indexed in Scilit:
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Learning curve for gastric cancer surgery based on actual survivalGastric Cancer, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Early palliative care for patients with advanced cancer: a cluster-randomised controlled trialThe Lancet, 2014
- Impact of timing and setting of palliative care referral on quality of end‐of‐life care in cancer patientsCancer, 2014
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Effects of a Palliative Care Intervention on Clinical Outcomes in Patients With Advanced CancerJAMA, 2009